AgomAb Therapeutics NV (AGMB) stock

AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30

$6.36+0.00 (0.00%)

Close on Nov 13, 2026Market cap $159.00KP/E –Yield –

AgomAb Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

AgomAb Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?